Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large ...
Chronic lymphocytic leukemia (CLL), the most common leukemia of adults in Western countries, is standing at a genuine ...
Morning Overview on MSN
The FDA cleared a three-drug maintenance combination for HER2-positive breast cancer built around tucatinib
Tucatinib, trastuzumab and pertuzumab became an approved maintenance regimen on Oct. 7, 2026, when the Food and Drug ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
Eli Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA in its first frontline indication for chronic ...
Health and Me on MSN
FDA approves targeted cancer drug as first-line treatment for CLL that cuts progression risk by 80%
The US Food and Drug Administration (FDA) recently approved pirtobrutinib for people with previously untreated chronic ...
Today's focus is on a new combination therapy for renal cell carcinoma approved by the US FDA on September 24, 2026. A drug ...
DeLLphi-305 randomized 563 nonprogressing ES-SCLC patients post induction durvalumab plus platinum/etoposide to durvalumab maintenance with or without tarlatamab, with overall survival as the primary ...
Christa Pike is the first known prisoner to survive a lethal injection. Christa Pike, a Tennessee death row inmate who ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results